{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447331147
| IUPAC_name = (2''E'')-1-{4-[2-Oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl}-3-(3,4,5-trimethoxyphenyl)-2-propen-1-one
| image = Cinepazide.svg

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->

<!--Identifiers-->
| ATC_prefix = C04
| ATC_suffix = AX27
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 67Y4P5C84X
| PubChem = 5282459
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1874750
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4445611
| smiles = O=C(N1CCCC1)CN3CCN(C(=O)\C=C\c2cc(OC)c(OC)c(OC)c2)CC3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C22H31N3O5/c1-28-18-14-17(15-19(29-2)22(18)30-3)6-7-20(26)25-12-10-23(11-13-25)16-21(27)24-8-4-5-9-24/h6-7,14-15H,4-5,8-13,16H2,1-3H3/b7-6+
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = RCUDFXMNPQNBDU-VOTSOKGWSA-N

<!--Chemical data-->
| C=22 | H=31 | N=3 | O=5 
| molecular_weight = 417.49864
}}

'''Cinepazide''' or '''cinepazide maleate'''<ref>{{Cite web|title = Anjieli, Kelinao, cinepazide maleate - Product Profile - BioCentury|url = http://www.biocentury.com/products/anjieli|website = www.biocentury.com|accessdate = 2015-08-04}}</ref> ('''Kelinao''' or '''Anjieli''' in China<ref name=drugs.com>Drugs.com [http://www.drugs.com/international/cinepazide.html Drugs.com International listings for cinepazide] Page accessed Aug 3, 2015</ref><ref name="Bocom Int">20 Oct 2010[http://www.bocomgroup.com/mediafiles/documents/p2_4743_en.pdf Sihuan Pharm – China's leading player in cardio-cerebral vascular drug – IPO Report]</ref>) is a [[vasodilator]] used in China for the treatment of cardiovascular and [[cerebrovascular diseases]], and [[peripheral vascular diseases]].<ref>Sihuan Pharmaceutical [http://www.sihuanpharm.com/index.php?a=show&m=Product&id=60&l=en Kelinao/Anjieli official site] Page accessed Aug 3, 2015</ref> It appears to work by potentiating A2 [[adenosine receptors]].<ref>Ruffolo RR Jr, et al. Drug receptors and control of the cardiovascular system: recent advances. Prog Drug Res. 1991;36:117-360. Review. {{PMID|1876708}} [https://books.google.com/books?id=tWT0BwAAQBAJ&pg=PA304 p 304]</ref>

==History==

Cinepazide was discovered by scientists at Laboratoires Delalande (now part of [[Sanofi]]) in 1969 in an effort to explore useful substituted [[cinnamoyl]]-[[piperazine]] compounds.<ref name=Sun/><ref>Cameron BD, et al The metabolic fate of the coronary vasodilator 4-(3,4,5-Trimethoxycinnamoyl)-1-(N-pyrrolidinocarbonylmethyl)piperazine (cinepazide) in the rat, dog and man. Xenobiotica. 1976 Jul;6(7):441-55. {{PMID|997590}} </ref>  The drug, in the form of a pill taken orally, was launched by Delalande in 1976 under the tradename Vasodistal, for treatment of [[heart failure]], [[balance disorders]], [[cerebrovascular disease]], and [[Vascular disease|vascular complications of diabetes]].<ref name=Sun>Johnson Sun for Guotai Junan International. Sept 28, 2011. [http://pg.jrj.com.cn/acc/Res%5CHK_RES%5CSTOCK%5C2011%5C9%5C28%5C5025ec90-2ed1-473d-bc50-4bc5affe1d83.pdf Company Report: Sihuan Pharmaceuticals]</ref><ref name=Reactions>Reactions Weekly 305(1):1. June 1990 [https://link.springer.com/article/10.2165/00128415-199003050-00001 Cinepazide-related agranulocytosis]</ref> In 1988 the drug was withdrawn from the market in Spain due to risk of [[agranulocytosis]]; other countries where the drug was available added warnings to the label.<ref name=Reactions/><ref>Laporte JR, Capellà D, Juan J.Agranulocytosis induced by cinepazide. Eur J Clin Pharmacol. 1990;38(4):387-8.  {{PMID|2344862}}</ref><ref>Department of Economic and Social Affairs of the United Nations Secretariat [https://www.un.org/esa/coordination/CL12.pdf Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals] United Nations – New York, 2005</ref> It was withdrawn from the market in France in 1992.<ref>Sidney M. Wolfe, M.D. for the Public Citizen's Health Research Group. February 2, 1995. [https://www.citizen.org/documents/1360.pdf Differences in the Number of Drug Safety Withdrawals: United States, United Kingdom, Germany and France 1970-1992]</ref> The drug had also been marketed in Japan by [[Daiichi]] under the brand name "Brindel"<ref name=drugs.com/> for dementia, but was withdrawn in 1999, following a review by the Japanese regulatory authorities of dementia drugs after a drug, [[Hopantenic acid|calcium hopantenate]], that had been considered the standard of care and against which cinepazide and other dementia drugs had been compared, had failed to demonstrate efficacy in a re-evaluation.<ref>Takeda M, Tanaka T, Okochi M. New drugs for Alzheimer's disease in Japan. Psychiatry Clin Neurosci. 2011 Aug;65(5):399-404. {{PMID|21851448}}</ref>

In 2002 [[Sihuan Pharmaceutical]] brought an injectable form of the drug to market in China;<ref name=Suisse/> Sihuan had acquired the drug from a military hospital in China that had developed the formulation.<ref name=SCB>Su Zhang for Standard Chartered Bank (HK) Limited. June 27, 2014 [http://www.fullertreacymoney.com/system/data/files/PDFs/2014/July/4th/China%20Healthcare.pdf China health care: Pharma sector comes of age]</ref>  In 2010 it was the highest selling drug in China, with about 1 billion RMB in sales in the 3rd quarter, outselling [[Plavix]] in China.<ref name=Suisse>Lefei Sun, Jinsong Du, and Iris Wang for Credit Suisse. October 6 2011 [https://doc.research-and-analytics.csfb.com/docView?language=ENG&source=ulg&format=PDF&document_id=917625241&serialid=jeGG48ExOvdMDxhWCQXH2AnbdTfWWpDCCuIE71n2tDU%3D China Pharma Sector]</ref><ref name="Bocom Int"/> This made Sihuan Pharm the largest company in China in the cardio-cerebral vascular drug market in 2010.<ref name="Bocom Int"/> In 2014 it was the tenth highest-selling drug in China.<ref name=SCB/>

==References==
{{reflist}}

{{Peripheral vasodilators}}

[[Category:Carboxamides]]
[[Category:Cinnamates]]
[[Category:Phenol ethers]]
[[Category:Piperazines]]
[[Category:Pyrrolidines]]